153 related articles for article (PubMed ID: 16974193)
1. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.
Chiu CC; Chen KP; Liu HC; Lu ML
J Clin Psychopharmacol; 2006 Oct; 26(5):504-7. PubMed ID: 16974193
[TBL] [Abstract][Full Text] [Related]
2. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.
Chiu CC; Chen CH; Chen BY; Yu SH; Lu ML
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):866-70. PubMed ID: 20394794
[TBL] [Abstract][Full Text] [Related]
3. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
[TBL] [Abstract][Full Text] [Related]
4. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Meyer JM
J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
[TBL] [Abstract][Full Text] [Related]
5. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
6. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
[TBL] [Abstract][Full Text] [Related]
7. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.
Yasui-Furukori N; Sato Y; Furukori H; Saito M; Nakagami T; Kaneko S
J Clin Psychiatry; 2009 Jan; 70(1):95-100. PubMed ID: 19026267
[TBL] [Abstract][Full Text] [Related]
8. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Chen CH; Chiu CC; Huang MC; Wu TH; Liu HC; Lu ML
Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):925-31. PubMed ID: 18082302
[TBL] [Abstract][Full Text] [Related]
9. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
[TBL] [Abstract][Full Text] [Related]
10. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
[TBL] [Abstract][Full Text] [Related]
11. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
12. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
[TBL] [Abstract][Full Text] [Related]
13. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.
Sowell MO; Mukhopadhyay N; Cavazzoni P; Shankar S; Steinberg HO; Breier A; Beasley CM; Dananberg J
J Clin Endocrinol Metab; 2002 Jun; 87(6):2918-23. PubMed ID: 12050274
[TBL] [Abstract][Full Text] [Related]
14. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.
Hardy TA; Henry RR; Forrester TD; Kryzhanovskaya LA; Campbell GM; Marks DM; Mudaliar S
Diabetes Obes Metab; 2011 Aug; 13(8):726-35. PubMed ID: 21435142
[TBL] [Abstract][Full Text] [Related]
15. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients.
Ingole S; Belorkar NR; Waradkar P; Shrivastava M
Indian J Physiol Pharmacol; 2009; 53(1):47-54. PubMed ID: 19810576
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.
Kaushal J; Bhutani G; Gupta R
Singapore Med J; 2012 Jul; 53(7):488-92. PubMed ID: 22815019
[TBL] [Abstract][Full Text] [Related]
17. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.
Manu P; Correll CU; Wampers M; van Winkel R; Yu W; Shiffeldrim D; Kane JM; De Hert M
Schizophr Res; 2013 Feb; 143(2-3):358-62. PubMed ID: 23231880
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
Kinon BJ; Liu-Seifert H; Ahl J; Ahmed S; Baker RW
Ann N Y Acad Sci; 2004 Dec; 1032():295-6. PubMed ID: 15677433
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.
Park S; Sang Mee Hong ; Il Sung Ahn ; Sung Hoon Kim
J Psychopharmacol; 2010 Jul; 24(7):1105-14. PubMed ID: 19965940
[TBL] [Abstract][Full Text] [Related]
20. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
Melkersson K; Berinder K; Hulting AL
Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
